Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer, AIDS Cure Claims By Swiss Super-Zapper Maker Draw FTC Complaint

This article was originally published in The Gray Sheet

Executive Summary

Internet ads claiming that the Super-Zapper Deluxe and Synchrometer devices are able to cure cancer, AIDS and other life-threatening diseases triggered a recent complaint from the Federal Trade Commission

You may also be interested in...



Internet Claims Regarding SARS Prevention Provoke Warning Letters

Eight manufacturers and distributors will receive 1warning letters, following a coordinated effort by the Federal Trade Commission, the FDA and the Ontario Ministry of Consumer and Business Services to "surf" the Internet for false and misleading claims related to Severe Acute Respiratory Syndrome

Internet Claims Regarding SARS Prevention Provoke Warning Letters

Eight manufacturers and distributors will receive 1warning letters, following a coordinated effort by the Federal Trade Commission, the FDA and the Ontario Ministry of Consumer and Business Services to "surf" the Internet for false and misleading claims related to Severe Acute Respiratory Syndrome

LASIK Centers’ Promotional Claims Draw FTC Complaints, Consent Order

LCA-Vision, Inc. and The Laser Vision Institute will be charged $11,000 per violation per day if the centers continue to make false, unsubstantiated claims about laser eye surgery, a Federal Trade Commission order states

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel